Opus Genetics Inc
IRD1.520USD
+0.030+2.01%
收盘 09/19, 16:00（美东）报价延迟15分钟
91.06M总市值
亏损市盈率 TTM
关于 Opus Genetics Inc 公司
Opus Genetics, Inc.（前身为 Ocuphire Pharma, Inc.）是一家临床阶段的眼科生物制药公司。该公司致力于开发治疗遗传性视网膜疾病 (IRD) 患者的疗法以及治疗其他视网膜和屈光疾病患者的疗法。其产品线包括基于腺相关病毒 (AAV) 的基因疗法，用于治疗导致不同形式的视网膜萎缩症、莱伯先天性黑蒙 (LCA) 和视网膜色素变性的基因突变。其最先进的基因治疗项目旨在治疗编码莱伯西林蛋白的 LCA5 基因突变，目前正在进行 I/II 期开放标签剂量递增试验，并正在获取早期数据。该管道还包括 0.75% 酚妥拉明眼液（一种非选择性 α-1 和 α-2 肾上腺素能拮抗剂，用于缩小瞳孔）和 APX3330（一种新型 Ref-1 小分子抑制剂，用于减缓非增生性糖尿病视网膜病变的进展）。
公司简介
公司代码IRD
公司名称Opus Genetics Inc
上市日期Nov 30, 2004
CEODr. George Magrath
员工数量18
证券类型Ordinary Share
年结日Nov 30
公司地址8 Davis Drive
城市DURHAM
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编27713
电话12486819815
网址https://opusgtx.com/
公司代码IRD
上市日期Nov 30, 2004
CEODr. George Magrath
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
691.31K
+247.13%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
318.65K
+33.24%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
254.82K
+51.80%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
200.00K
--
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+29.21%
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Chief Operating Officer
54.50K
+2625.00%
Dr. Benjamin R. Yerxa, Ph.D.
Dr. Benjamin R. Yerxa, Ph.D.
President, Director
President, Director
10.00K
-97.08%
Dr. Ash Jayagopal, Ph.D.
Dr. Ash Jayagopal, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
--
--
Dr. James S. Manuso
Dr. James S. Manuso
Independent Director
Independent Director
--
--
Dr. Jean Bennett, M.D., Ph.D.
Dr. Jean Bennett, M.D., Ph.D.
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
691.31K
+247.13%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
318.65K
+33.24%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
254.82K
+51.80%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
200.00K
--
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+29.21%
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Chief Operating Officer
54.50K
+2625.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月17日 周三
更新时间: 9月17日 周三
持股股东
股东类型
持股股东
持股股东
占比
Foundation Fighting Blindness Inc
15.06%
Perceptive Advisors LLC
6.86%
Bios Equity Partners, LP.
5.84%
Nantahala Capital Management, LLC
5.31%
Gallagher (Cam S)
2.87%
其他
64.06%
持股股东
持股股东
占比
Foundation Fighting Blindness Inc
15.06%
Perceptive Advisors LLC
6.86%
Bios Equity Partners, LP.
5.84%
Nantahala Capital Management, LLC
5.31%
Gallagher (Cam S)
2.87%
其他
64.06%
股东类型
持股股东
占比
Corporation
15.06%
Hedge Fund
8.62%
Individual Investor
7.02%
Private Equity
6.86%
Venture Capital
5.87%
Investment Advisor
3.25%
Investment Advisor/Hedge Fund
2.71%
Research Firm
0.40%
Bank and Trust
0.04%
其他
50.18%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
129
27.24M
45.65%
+17.32M
2025Q1
138
20.65M
39.75%
+13.58M
2024Q4
131
8.86M
28.50%
+3.96M
2024Q3
122
4.55M
16.47%
-580.64K
2024Q2
124
4.74M
17.35%
-706.54K
2024Q1
127
5.24M
21.33%
-1.10M
2023Q4
122
5.21M
22.35%
-525.41K
2023Q3
117
4.91M
22.05%
-1.09M
2023Q2
119
4.95M
23.60%
-1.34M
2023Q1
103
4.98M
23.80%
-1.17M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Foundation Fighting Blindness Inc
9.49M
15.91%
+6.93M
+270.10%
Apr 30, 2025
Perceptive Advisors LLC
4.33M
7.25%
+4.33M
--
Mar 31, 2025
Bios Equity Partners, LP.
995.25K
1.67%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.16M
5.29%
+3.16M
--
Mar 31, 2025
Gallagher (Cam S)
940.87K
1.58%
+79.50K
+9.23%
Apr 30, 2025
Opaleye Management Inc.
1.18M
1.97%
+1.18M
--
Mar 31, 2025
Mink Brook Asset Management LLC
810.08K
1.36%
+810.08K
--
Mar 31, 2025
The Vanguard Group, Inc.
992.20K
1.66%
--
--
Mar 31, 2025
Bleichroeder LP
736.84K
1.24%
+736.84K
--
Mar 31, 2025
Magrath (George)
691.31K
1.16%
+492.16K
+247.13%
Mar 24, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Value ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
占比0%
Avantis US Small Cap Value ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
公告日期
类型
比率
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
